This study is a 2-arm, double blinded, randomised clinical trial where 40 participants will be assigned 1:1 to insulin treatment alone (control) or insulin treatment and tirzepatide treatment for 32 weeks. The primary objective is to demonstrate that tirzepatide treatment, dose incremented to 15mg QW for 32 weeks adjunctive to insulin treatment can reduce body weight in patients with T1D and overweight or obesity when compared to insulin treatment alone. The secondary objective is to demonstrate that tirzepatide treatment, dose incremented to 15mg QW for 32 weeks can improve glycaemic control (measured by hbA1c), improve time in range, reduce insulin requirements, and reduce the severity of comorbidities in people with obesity and T1D. This trial includes a 6 month follow-up period.

Start Date01 Dec 2026

Sponsor / Collaborator

Royal North Shore Hospital

NCT07468552

/ Not yet recruitingPhase 2IIT

Randomized, Double-Blind, Placebo-Controlled Pilot Trial of Tirzepatide for Treatment of Cannabis Use Disorder (CUD)

The purpose of this randomized, double-blind, placebo-controlled, multi-site clinical trial is to evaluate the safety and efficacy of tirzepatide in a sample of 100 patients diagnosed with moderate or severe CUD by DSM-5 criteria.

Start Date15 Nov 2026

Sponsor / Collaborator

National Institute on Drug Abuse

100 Clinical Results associated with Tirzepatide

100 Translational Medicine associated with Tirzepatide

100 Patents (Medical) associated with Tirzepatide

1,971

Literatures (Medical) associated with Tirzepatide

31 Dec 2026·JOURNAL OF MEDICAL ECONOMICS

Enhancing economic modelling in obesity: integrating novel type 2 diabetes progression & obstructive sleep apnea remission – a UK case study

Article

Author: Zimner-Rapuch, Sarah ; Annemans, Lieven ; van Hest, Naomi ; Johansson, Erin ; Wilding, John P. H. ; Grist, Josephine ; Spaepen, Erik

PURPOSE:

This study presents an updated health economic model for evaluating the long-term cost-effectiveness of interventions in overweight and obesity, integrating new clinical evidence from the SURMOUNT clinical trial programme and methodological advancements in type-2 diabetes and obstructive sleep apnea (OSA) modelling.

PATIENTS AND METHODS:

An updated individual patient simulation model evaluated the costs and long-term clinical outcomes of tirzepatide (5, 10, 15.0 mg) versus diet and exercise (D&E) alone in patients with a body mass index (BMI) ≥30 kg/m² (obesity), or BMI ≥27 to <30 kg/m² (overweight) + ≥1 obesity-related complication with a UK healthcare perspective. Key improvements over a previously published model were introduced, including modelling remission and progression of OSA, capturing realistic patterns of D&E discontinuation, incorporating HbA1c as a continuous cardiometabolic endpoint and transition to R-based implementation over VBA. Primary results include incremental cost-effectiveness ratios (ICERs; cost/QALY), costs, life years gained and quality-adjusted life years (QALYs). Secondary outcomes including clinical outcomes, random seed and cohort convergence, deterministic sensitivity results and run time were also calculated.

RESULTS:

The refined model predicted that all tirzepatide doses were cost-effective compared to D&E at a £20,000/QALY gained WTP (willingness-to-pay) threshold (ICERs: £8,327-£10,157). Refined estimation of long-term D&E discontinuation and OSA remission likely contributed to lower incremental costs, higher QALYs, and reduced ICERs compared with the previous model, aligning outcomes more closely with expected benefits from weight management treatment. Transitioning to R-based implementation reduced run time (e.g. by 4.52 h for deterministic sensitivity analyses) and enhanced model stability in all analyses conducted.

CONCLUSION:

This enhanced economic model represents a significant advancement in the evaluation of obesity pharmacotherapy, designed to enhance clinical relevance, technical robustness, and increase usability. It supports evidence-based decision-making for chronic weight management treatment in the UK, and beyond, while offering a scalable platform for future therapeutic evaluations.

31 Dec 2026·JOURNAL OF MEDICAL ECONOMICS

Annual pharmacy cost per patient achieving composite treatment endpoints: a cost to target analysis of tirzepatide versus subcutaneous semaglutide 1 mg in patients with type 2 diabetes in the UK

Article

Author: Kanumilli, Naresh ; Evans, Jerome ; Cattin, Juliette ; Debackere, Nele ; Osumili, Beatrice ; Buckingham, Mike ; Hunt, Barnaby ; Webb, Joanne ; Nowakowski, Piotr

INTRODUCTION:

Tirzepatide is a treatment for type 2 diabetes associated with improvements in glycemic control and weight loss, and a low risk of hypoglycemia when not used in combination with insulin or insulin secretagogues. A cost to target analysis of tirzepatide 5, 10 and 15 mg versus subcutaneous semaglutide 1 mg in the UK setting was performed, calculating the annual pharmacy cost per patient treated to six composite endpoints combining glycemic control (glycated hemoglobin [HbA1c] ≤ 6.5% [48 mmol/mol] and <7.0% [53 mmol/mol]) with weight loss (≥5%, ≥10%, ≥15%) and avoidance of hypoglycemia. The costing analysis was based on the tirzepatide costs appraised by NICE as part of TA924.

METHODS:

The proportions of patients achieving composite treatment targets with tirzepatide and semaglutide (both in combination with metformin) were taken from a post-hoc analysis of the SURPASS-2 clinical trial (N = 1,845). Costs per patient treated to target were calculated by dividing the annual treatment costs associated with each intervention by the proportion of patients achieving the treatment target with each intervention.

RESULTS:

Tirzepatide 5, 10 and 15 mg were associated with a lower pharmacy cost per patient achieving treatment target than semaglutide 1 mg for the majority of endpoints evaluated. Differences became greater at more strict treatment targets. For example, the cost per patient achieving HbA1c ≤6.5%, weight loss ≥15%, and no hypoglycemia was GBP 5,650, GBP 8,665 and GBP 9,462 lower with tirzepatide 5, 10 and 15 mg, respectively, compared with semaglutide 1 mg over a 1-year time horizon. The only endpoint where semaglutide 1 mg was associated with a lower cost per patient achieving target was HbA1c <7.0%, weight loss ≥5%, and no hypoglycemia.

CONCLUSIONS:

Compared to semaglutide, tirzepatide was associated with a lower annual pharmacy cost per patient with diabetes achieving treatment target in the UK for the majority of endpoints, with greater differences at more strict treatment targets.

31 Dec 2026·JOURNAL OF MEDICAL ECONOMICS

Cost-effectiveness of tirzepatide versus semaglutide for patients with obesity or overweight in the US: evidence from the SURMOUNT-5 head-to-head phase-3 trial

Article

Author: Zimner-Rapuch, Sarah ; Kirk, Myles ; Johansson, Erin ; van Hest, Naomi ; Annemans, Lieven ; Bays, Harold ; Wilding, John P. H. ; Spaepen, Erik ; Upadhyay, Navneet

PURPOSE:

This study evaluated the cost-effectiveness (from the United States [US] societal perspective) of tirzepatide at its maximum-tolerated-dose (MTD) compared to semaglutide (MTD), both administered adjunct to a reduced-calorie diet and increased physical activity. The analysis focused on individuals with obesity (body mass index [BMI] ≥ 30 kg/m²), or overweight (BMI ≥27 to <30 kg/m² + ≥1 obesity-related complication), using data from the head-to-head Phase-3 SURMOUNT-5 trial (patients without type 2 diabetes [T2D]).

PATIENTS AND METHODS:

This patient-level simulation modeling study assessed the cost and long-term clinical outcomes of tirzepatide (MTD) versus semaglutide (MTD), using data from the SURMOUNT-5 trial population. The modeled population were at risk of developing obesity-related complications including cardiovascular disease (CVD) and obstructive sleep apnea (OSA), amongst others. These outcomes were modeled using cardiometabolic parameters including weight, systolic blood pressure, high-density lipoprotein, glycated hemoglobin (HbA1c) and total cholesterol, by assessing their impact on healthcare and wider societal costs, quality of life, and mortality. Incremental cost-effectiveness ratios (ICERs; cost/quality-adjusted life year [QALY]) and incremental net health benefit (iNHBs) were calculated, and uncertainty was assessed through sensitivity and scenario analyses.

RESULTS:

Tirzepatide (MTD) was estimated to be less costly and more efficacious compared to semaglutide (MTD) with per patient cost savings of $41,688, 0.506 QALYs gained and positive iNHB of 0.784, indicating a net health benefit for tirzepatide. The model predicted that per 1,000 patients, 70 fewer patients will develop T2D, 10 fewer will develop CVD with tirzepatide (MTD) and patients spend 3.07 more years living with moderate/severe OSA when treated with semaglutide (MTD).

CONCLUSION:

Based on this simulation model, using head-to-head SURMOUNT-5 trial data, tirzepatide (MTD) had lower total costs and higher QALYs compared to semaglutide (MTD). This supports that tirzepatide (MTD) is a cost-effective treatment option for individuals with obesity or overweight compared to semaglutide (MTD).

1,962

News (Medical) associated with Tirzepatide

17 Jul 2026

·www.prnewswire.com

Study Finds Some Medical Spas Still Selling Compounded Weight-Loss Drugs From Pharmacies With Regulatory Concerns

CU Anschutz researchers found the compounded GLP-1 market remains robust after FDA shortages ended, with some products supplied by pharmacies lacking sterile compounding licenses or with recent disciplinary histories AURORA, Colo., July 17, 2026 /PRNewswire/ - Despite the end of federal shortages of popular GLP-1 weight-loss medications, the market for compounded alternatives remains strong – and some patients may unknowingly be receiving products from pharmacies with concerning regulatory histories, according to new research from the University of Colorado Anschutz. Published today in JAMA Health Forum, the study found that many weight-loss clinics and medical spas continue to sell compounded versions of GLP-1 medications such as semaglutide and tirzepatide. Researchers also identified suppliers that lacked licenses required for sterile compounding or had recently been subject to disciplinary actions related to sterile compounding practices. "Our findings suggest this market didn't shrink after the shortages ended as many expected," said lead author Michael J. DiStefano, PhD, MBE, assistant professor at the University of Colorado Anschutz Skaggs School of Pharmacy and Pharmaceutical Sciences. "Instead, it has remained remarkably robust, raising important questions about how these products are regulated and how patients can know whether they're receiving medications that meet appropriate quality standards." Compounded GLP-1 drugs expanded rapidly during nationwide shortages of Wegovy and Zepbound, when federal regulations temporarily allowed pharmacies to compound copies of medications in short supply. Researchers wanted to know what happened after those shortages ended and the FDA resumed enforcement against routine copies of commercially available products. DiStefano and colleagues examined brick-and-mortar weight-loss clinics and medical spas, an area that has received less scrutiny than online telehealth despite serving many patients. Using a "secret shopper" approach, researchers contacted businesses in Oklahoma and West Virginia to ask what products were available, how patients were monitored and where the medications were sourced. The team identified 75 clinics and medical spas offering compounded GLP-1 medications. Instead of seeing the market disappear, the researchers found evidence that many compounded products now include added ingredients, such as vitamin B12, which may be presented as individualized formulations. "One concern is whether we're seeing clinically meaningful personalization or changes that primarily allow compounded products to remain on the market," DiStefano said. "For many of these added ingredients, we simply don't have good evidence showing they improve safety or effectiveness." Additionally, among the 23 compounding pharmacies supplying these businesses, four lacked licenses for sterile compounding, while several had recent disciplinary actions or FDA warning letters related to sterile compounding practices. DiStefano emphasized that compounded GLP-1 medications have helped expand access for patients who cannot afford brand-name drugs or whose insurance does not cover obesity treatment. However, he said patients should not have to choose between affordability and quality. "This market has grown so large and diffuse that it's difficult for regulators to oversee every pharmacy supplying these medications," he said. "Our findings suggest there's a need for regulatory innovation that preserves access while giving patients greater confidence that the products they're receiving are safe and appropriately manufactured." The researchers hope the findings encourage clinicians and patients to ask more questions about where compounded medications originate and whether the pharmacies producing them meet appropriate standards for sterile compounding. Key Takeaways: Compounded GLP-1 medications remain widely available at many weight-loss clinics and medical spas despite the end of FDA shortages. Some clinics reported sourcing medications from pharmacies with regulatory concerns, including a lack of sterile compounding licenses or recent disciplinary actions. The study did not evaluate the safety or quality of the medications. It examined how compounded GLP-1 products are marketed and sourced. Researchers say patients should not have to choose between affordability and quality and call for greater transparency and oversight while preserving access. Frequently Asked Questions: What did the study find? A University of Colorado Anschutz study published in JAMA Health Forum found that many weight-loss clinics and medical spas continue to offer compounded GLP-1 medications after FDA shortages ended. The researchers also identified some suppliers that lacked sterile compounding licenses or had recent disciplinary actions related to sterile compounding practices. Does this study show that compounded GLP-1 medications are unsafe? No. The University of Colorado Anschutz study did not evaluate the safety, quality or effectiveness of compounded GLP-1 medications. Instead, it examined how these medications are marketed and sourced by weight-loss clinics and medical spas. Why is this study important? The study highlights the need for greater transparency and oversight in the growing market for compounded GLP-1 medications. It also emphasizes that patients should not have to choose between affordable obesity treatment and confidence in the quality of their medications. Why are patients still using compounded semaglutide and tirzepatide? Many patients use compounded semaglutide and tirzepatide because brand-name GLP-1 medications can be expensive or are not covered by insurance. Compounded medications have expanded access to obesity treatment for many people. What should patients know before using compounded GLP-1 medications? Patients should talk with their healthcare provider about why a compounded GLP-1 medication is recommended, where it is produced, and whether the pharmacy meets appropriate sterile compounding standards. Patients should not stop taking prescribed medication based on this study alone without consulting their healthcare provider. Contact: Kelsea Pieters, CU Anschutz [email protected], Phone: (804) 314-1360 SOURCE University of Colorado Anschutz 21% more press release views with Request a Demo

17 Jul 2026

·www.pharmaceutical-technology.com

MSD wins FDA approval for cholesterol pill to help plug Keytruda void

Lipfendra’s presence as the only oral PCSK9 inhibitor on the market represents a significant growth opportunity for MSD. Credit: HJBC/Shutterstock.com. MSD (Merck & Co) has won US Food and Drug Administration (FDA) approval for its cholesterol-lowering pill, marking a significant milestone in the drugmaker’s push to reduce revenue reliance on Keytruda (pembrolizumab). The FDA has approved MSD’s Lipfendra (enlicitide) to reduce low-density lipoprotein cholesterol (LDL-C) in adults with high cholesterol or who have an inherited type of high cholesterol called heterozygous familial hypercholesterolemia (HeFH). Lipfendra, which is to be used in tandem with diet and exercise, is a tablet taken once a day. The marketing authorisation means MSD has beaten AstraZeneca to market the first PCSK9 inhibitor in pill form. AstraZeneca is hoping to unlock this indication with laroprovstat, which is still in Phase III trials. LDL-C, also known as “bad” cholesterol, causes plaque to build up in vessels, increasing the risk of heart attacks and strokes. While lifestyle habits can cause high levels, genetics can also play a role, such as the inherited disorder HeFH. About 86 million US adults age 20 or older have total cholesterol levels above the recommended level, according to the US Centers for Disease Control and Prevention (CDC). In one study (NCT05952856) in MSD’s Phase III programme, Lipfendra reduced LDL-C by 56% compared to placebo, and this rose to 60% when accounting for negligible baseline levels. In another trial (NCT05952869), it cut LDL-C by 59% compared to placebo. The drug also led to further benefits associated with atherosclerotic cardiovascular disease (ASCVD) risk, and its safety profile was similar to placebo, though diarrhoea and dizziness occurred at higher rates in one of the studies. There are many options to treat high cholesterol, including statins, ezetimibe, and PCSK9 inhibitors. The latter class, which until now were only available in injectable form, works by enabling the liver to recycle more receptors that sweep LDL-C from the blood. Amgen’s Repatha (evolocumab) and Regeneron/Sanofi’s Praluent (alirocumab) dominate this landscape. Katherine Wilemon, CEO of the non-profit Family Heart Foundation, commented: “We are encouraged by the approval of a new oral PCSK9 inhibitor option for adults who need additional LDL-C lowering.” MSD sharpens post-Keytruda strategy Lipfendra’s presence as the only oral PCSK9 inhibitor on the market represents a significant growth opportunity for MSD. Executives at the company have previously touted the commercial opportunity, though they have not yet placed a sales forecast on the medicine. GlobalData forecasts $3.5bn in global sales for Lipfendra in 2032. GlobalData is the parent company of Pharmaceutical Technology . MSD is contending with the impending loss of exclusivity for its flagship product Keytruda. For three years, the pan-solid tumour drug was the world’s top-selling medication, generating peak sales of $31.7bn in 2025. It has since been usurped by Eli Lilly’s weight loss drug Mounjaro (tirzepatide). Keytruda’s core US patent expires in late 2028, with other regions following thereafter, forcing the big pharma company to diversify its portfolio to plug the looming revenue hole. It is doing this through a mixture of in-house R&D and business development. The latter strategy saw MSD strike agreements to buy respiratory disease drug developer Verona Pharma for $10bn in July 2025 and antiviral specialist Cidara Therapeutics for $9.2bn in November 2025, amongst others. Citi analysts said in a research note: “We see Lipfendra as an important addition to MSD’s broader effort to diversify growth drivers and build greater exposure in cardiometabolic disease as Keytruda loss of exclusivity approaches”. Dutch-based biotech NewAsmterdam’s cholesterol-lowering therapy obicetrapib, which targets the Cholesteryl Ester Transfer Protein (CETP), has been linked to a decrease in a key biomarker of Alzheimer’s disease . This suggests that drugs that clear cholesterol could have benefits in other diseases.

Phase 3Clinical ResultDrug ApprovalAcquisition

16 Jul 2026

·www.pharmaindustrial-india.com

Ascletis Selects Oral ASC30-ASC48 Fixed-Dose Combination for Clinical Development in Obesity

Ascletis Pharma has announced the selection of a Fixed-Dose Combination (FDC) of ASC48, an investigational oral small-molecule Glucose-Dependent Insulinotropic Polypeptide Receptor (GIPR) agonist, and ASC30, an oral glucagon-like peptide-1 receptor (GLP-1R) agonist, for clinical development as a potential once-daily treatment for obesity. The combination therapy, ASC30_48 FDC, is being developed as a potentially first-in-class oral, single-pill regimen targeting both GLP-1R and GIPR, with the aim of providing an alternative to injectable obesity therapies. ASC48 was discovered using Ascletis' proprietary Artificial Intelligence-assisted Structure-Based Drug Discovery (AISBDD) platform. According to the company, the candidate demonstrated high potency in preclinical studies, with an EC50 of 1 pM in the human GIPR cAMP activation assay, compared with 3 pM for tirzepatide. The molecule also showed selective activity for GIPR, without activation of GLP-1R or glucagon receptors (GCGR). Preclinical pharmacokinetic studies in rodents and non-human primates demonstrated favourable oral bioavailability, sustained drug exposure and a long half-life, supporting the potential for once-daily oral administration in humans. In a head-to-head non-human primate study, the ASC30_48 fixed-dose combination achieved approximately 52 percent greater relative body weight reduction than ASC30 monotherapy, indicating the potential benefits of dual receptor activation for obesity management. Ascletis expects to submit an Investigational New Drug (IND) application for the oral fixed-dose combination tablets to the US Food and Drug Administration (FDA) in the fourth quarter of 2026, paving the way for clinical evaluation. Commenting on the development, Jinzi Jason Wu, Ph.D., Founder, Chairman and CEO of Ascletis, said the company aims to evaluate the fixed-dose combination as a potentially first-in-class oral therapy for obesity. He added that the programme is intended to address the need for an oral treatment capable of delivering weight-loss efficacy and tolerability comparable to currently available dual agonist injectable therapies. Ascletis Pharma is a fully integrated biotechnology company focused on developing and commercialising first-in-class and best-in-class therapies for metabolic diseases, leveraging artificial intelligence to accelerate drug discovery and development.

100 Deals associated with Tirzepatide

External Link

KEGG	Wiki	ATC	Drug Bank
D11360	Tirzepatide	-	DB15171

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Obesity Hypoventilation Syndrome	China	Eli Lilly Suzhou Pharmaceutical Co. Ltd.	30 Jun 2025
Sleep Apnea, Obstructive	United States	Eli Lilly & Co.	20 Dec 2024
Obesity	United States	Eli Lilly & Co.	08 Nov 2023
Overweight	United States	Eli Lilly & Co.	08 Nov 2023
Weight Gain	Australia	Eli Lilly Australia Pty Ltd.	23 Dec 2022
Diabetes Mellitus, Type 2	United States	Eli Lilly & Co.	13 May 2022

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Heart failure with normal ejection fraction	NDA/BLA	China	Eli Lilly & Co.	22 Nov 2024
Reduced ejection fraction co-occurrent and due to chronic heart failure	NDA/BLA	European Union	Eli Lilly & Co.	-
Metabolic dysfunction-associated steatotic liver disease	Phase 3	United States	Eli Lilly & Co.	16 Oct 2025
Colitis, Ulcerative	Phase 3	United States	Eli Lilly & Co.	26 Jun 2025
Colitis, Ulcerative	Phase 3	Austria	Eli Lilly & Co.	26 Jun 2025
Colitis, Ulcerative	Phase 3	Belgium	Eli Lilly & Co.	26 Jun 2025
Colitis, Ulcerative	Phase 3	Brazil	Eli Lilly & Co.	26 Jun 2025
Colitis, Ulcerative	Phase 3	Bulgaria	Eli Lilly & Co.	26 Jun 2025
Colitis, Ulcerative	Phase 3	Canada	Eli Lilly & Co.	26 Jun 2025
Colitis, Ulcerative	Phase 3	Czechia	Eli Lilly & Co.	26 Jun 2025

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04255433 (SURPASS-CVOT \| SURPASS, CTgov)	Phase 3	Diabetes Mellitus, Type 2	13,299	Dulaglutide	jcncdbebrx = uaalhzdzav omugptqxih (qglvgzuekn, xpfzuadqzy - vokduaoptw) View more	-	08 Jul 2026
ADA2026	Not Applicable	Diabetes Mellitus, Type 2	12,500	Tirzepatide	wpkyejwsjk(bfzpkegalq): RR = 1.08 (95.0% CI, 0.97 - 1.2)	Positive	20 Jun 2026
				Semaglutide
ADA2026	Not Applicable	Overweight \| Obesity	181	Tirzepatide	wsnszswhec(rzkeeoadqr) = wdggjcirjm jnxcyvaaho (wdwkqhkmwl, 80.7 - 91.2) View more	Positive	20 Jun 2026
NCT05260021 (SURPASS-PEDS, ADA2026)	Phase 3	Diabetes Mellitus, Type 2	99	Tirzepatide 5 mg	pluzpwrsbd(ohyobtngwa) = ryuhjyedvi btsgoxiwxu (lekxiyjimn )	Positive	20 Jun 2026
				Placebo	pluzpwrsbd(ohyobtngwa) = fzwrcwkxqd btsgoxiwxu (lekxiyjimn )
ADA2026	Not Applicable	Diabetes Mellitus, Type 2	71	Tirzepatide (Type 2 Diabetes Mellitus)	ykdasyyoke(gihfvkgsbt) = Gastrointestinal adverse events were common (59.2%) but predominantly mild to moderate. No severe hypoglycemia or serious adverse events occurred. legkxowyog (rsnsgimseq )	Positive	20 Jun 2026
ADA2026	Not Applicable	Diabetes Mellitus, Type 2 \| Peripheral Arterial Disease	24,374	Tirzepatide	zhpdlclnju(oaxjchaazr): RR = 0.65 (95.0% CI, 0.45 - 0.92), P-Value = 0.015	Positive	20 Jun 2026
				Injectable Semaglutide
EULAR2026	Not Applicable	Arthritis, Psoriatic	73	Tirzepatide+biologic	dxapugcbgr(npsdtrtpaf) = tqrlicjsvl fsqlouccry (mikghhmlmy ) View more	Positive	11 Jun 2026
				biologic	fjywbcfzka(svfbvqyfqh) = vrshrclqdm pclexsunwv (ydqzupplsv ) View more
NCT06588296 (TOGETHER-PSA, EULAR2026)	Phase 3	Arthritis, Psoriatic	271	IXEKIZUMAB AND CONCOMITANT TIRZEPATIDE	twviqsmkra(xyplgnuwdp) = lrsvqwtssh niozukmaov (tpsecofmro ) View more	Positive	11 Jun 2026
				IXEKIZUMAB	twviqsmkra(xyplgnuwdp) = ziwkiqbtrf niozukmaov (tpsecofmro ) View more
NCT04255433 (Pubmed \| JAMA Cardiol)	Phase 3	Cardiovascular Diseases \| Diabetes Mellitus, Type 2	13,165	Tirzepatide	hgfmvstcjj(wnrughlabc) = bbtbdwmfpy hyvtocxghq (fqqwdsatyp ) View more	Positive	01 Jun 2026
				Dulaglutide	hgfmvstcjj(wnrughlabc) = hgoxdaylef hyvtocxghq (fqqwdsatyp ) View more
NCT05963022 (SURPASS-CN-MONO, Pubmed \| Med)	Phase 3	Early-onset type II diabetes	206	5 mg Tirzepatide	capxocgbty(orsslxbsgm) = zsmyklfygs dywlwdouhu (xzasevouxq ) View more	Positive	01 Jun 2026
				10 mg Tirzepatide	capxocgbty(orsslxbsgm) = kzqqwvlkhs dywlwdouhu (xzasevouxq ) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis